Avsnitt
-
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the latest news in pathogen activity and how these viruses serve as an important reminder of the role of the public-private lab partnership.
Their discussion includes:
How the United States addresses emerging pathogens and the importance of a partnership between public health laboratories and private or clinical laboratories.Why access to testing is vital to prevent pathogen outbreaks and pandemics.The need for an effective legal framework around pandemic and hazard preparedness.Current diagnostic efforts around mpox, bird flu, and COVID-19, and opportunities to expand at-home testing. -
Matthew Schultz, Ph.D., and Amy White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.
(00:31)
Would you share a little bit about yourself and your background?(01:11)
Could you provide us with an overview of this particular peripheral neuropathy?(03:09)
Can you share the background as to how your team learned about this condition and how you considered testing for it?(04:42)
Would you explain what you saw when you performed the urine test on the first patient?
(05:26)
Were you able to test additional patients with this condition?(06:09)
Could you expand on why this urine test is important?
(07:20)
How does a health care provider order urine testing for SORD deficiency?(07:59)
How does this new SORD urine test complement the existing Mayo Clinic Laboratories test menu?(08:55)
Could you summarize the benefits of ordering this SORD urine test at Mayo?
-
Saknas det avsnitt?
-
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by special guest Donald Thomas, M.D., a rheumatologist and lupus researcher. They discuss how Mayo Clinic Laboratories’ suite of innovative lupus testing, offered in collaboration with Progentec Diagnostics, is enhancing the care and quality of life for patients affected by systemic lupus erythematosus (SLE).
Their discussion includes:
Symptoms of lupus and characteristics of the complex disease process.The role of laboratory testing in diagnosing and managing long-term treatment for patients with lupus.Dr. Thomas’ clinical experience using the Progentec aiSLE® DX Lupus Flare Risk Index and Lupus Disease Activity Index for his patients, and how these tests have enhanced collaborative treatment planning.Why these novel tests are a major step forward in expanding diagnostic tools and improving care for patients living with SLE. -
John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.
Show notes
Speaker 3: (00:32)
Would you provide a little background on yourself, Dr. Mills?Speaker 3: (01:19)
Dr. Dubey?Speaker 3: (02:07)
Can you give a brief overview of our demyelinating test and recommended use?Speaker 3: (03:52)
Can you discuss how this new test will assist in a patient's journey?Speaker 3: (05:46)
Can you tell us some of the unique features of this test?Speaker 3: (08:09)
Dr. Dubey, as a neurologist, how does this test set us apart in the market?Speaker 3: (11:05)
Could you summarize the benefits of having both a demyelinating panel and an axonal panel?Speaker 3: (11:40)
Why should a patient have an axonal or demyelinating test versus a sensory and motor test for peripheral neuropathy? -
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by special guests Bernard Rubin, D.O., MPH, chief medical officer of Progentec Diagnostics, and Melissa Munroe, M.D., Ph.D., chief scientific officer and principal investigator of Progentec Diagnostics. They discuss Mayo Clinic Laboratories’ suite of innovative lupus testing, offered in collaboration with Progentec Diagnostics, for patients affected by systemic lupus erythematosus (SLE).
Their discussion includes:
The Progentec aiSLE® DX Lupus Flare Risk Index that uses an algorithm to calculate a flare risk index, which assigns a score based on a patient's risk of a forthcoming lupus flare.The Progentec aiSLE® DX Lupus Disease Activity Index that characterizes a patient’s current disease activity into low, moderate, or active states.How these two tests were developed and for whom they are recommended.Why these tests are a significant development and how they enhance the quality of life for patients living with SLE. -
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.
Speaker 3: (00:32)
Would you tell us a little bit about yourself and your history with this testing?Speaker 3: (01:25)
Would you tell us a little more about this assay?Speaker 3: (04:57)
Which patients should have this testing and when should it be performed?Speaker 3: (05:30)
What alternative tests exist and how do they compare?Speaker 3: (06:28)
How are the results used in patient care? -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the latest advancements in Alzheimer’s disease testing and treatment.
Their discussion includes:
Why there is an increased focus on Alzheimer’s disease in the diagnostics industry.The development of groundbreaking blood tests that can detect Alzheimer’s-related biomarkers.The importance of accurate testing to avoid false positives.The role of laboratory scientists in guiding appropriate test usage.The promising new treatment options and the need for informed decision-making in a patient’s healthcare journey. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They cover current trends, pain points, and opportunities for growth in the lab and diagnostics market.
Their discussion includes:
Insights from Dr. Morice’s participation in an Advisory Board webinar about 2024 lab market trends.Why there is an increased demand for laboratory testing.The opportunities that come with digital pathology, at-home testing, and remote diagnostics. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Matthew Binnicker, Ph.D., professor of laboratory medicine and pathology and clinical virologist at Mayo Clinic. They discuss the upsurge of mpox cases, particularly in Africa, and why the World Health Organization has declared it a public health emergency of international concern.
Specific topics of discussion include:
Background information on the monkeypox virus, and the current outbreak situation.What is contributing to the rapid spread of mpox in the Democratic Republic of the Congo and neighboring countries.How the current mpox outbreak compares to the global outbreak in 2022, and lessons learned that could be applied today.Testing options for diagnosing mpox.What can be done to control the spread of mpox and prevent future outbreaks. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss what’s new and ongoing with pathogens and infections.
Their discussion includes:
Summer cases of COVID-19.H5N1 (avian influenza) activity and testing options.Increasing dengue fever infections.Outbreaks of listeria and cyclospora.The importance of public-private partnerships in preventing disease outbreaks and increasing access to testing. -
Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of patients with inflammatory bowel disease.
Speaker 4: (00:32)
Please give the audience a little information about yourself and your background.Speaker 4: (02:12)
Please give the audience a brief overview of this assay.Speaker 4: (04:34)
Which patients should have this testing and when should it be performed?Speaker 4: (05:50)
What alternative testing options are available and how do these compare?Speaker 4: (06:47)
How are the results used in patient care? -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss insights from Dr. Morice’s recent travels abroad, including biomanufacturing, diagnostics, cybersecurity, and supply chain activities.
Their discussion includes:
What’s happening in the global diagnostics industry and takeaways from visiting Saudi Arabia and Italy.Why countries are looking toward building their own biomanufacturing and diagnostic resources, and the impacts of a global supply chain.The evolution of digitalization and cybersecurity. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Elitza Theel, Ph.D., director of the Infectious Diseases Serology Laboratory at Mayo Clinic, to discuss the increase of dengue cases in the United States and around the world.
Specific topics of discussion include:
The characteristics and symptoms of dengue virus.Current dengue activity in the United States, why cases are increasing, and how it may impact public health.Whether an individual infected with dengue has future immunity against the virus.Laboratory tests used to detect and diagnose dengue.How to protect against dengue and other vector-borne diseases. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss how healthcare is a logical space to apply artificial intelligence (AI) technology and trends in how AI is being utilized.
Their discussion includes:
The benefits and pitfalls of using AI in clinical settings.Important factors to consider before implementing AI tools in the laboratory.A successful AI use case from the Parasitology Lab at Mayo Clinic, and how it enhanced turnaround times and staff satisfaction. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss a case that was recently overturned by the Supreme Court of the United States that may have ramifications for the healthcare industry, including impacts on regulatory oversight.
Their discussion includes:
A summary of the Supreme Court ruling on June 28 to overturn the 1984 Chevron v. Natural Resources Defense Council decision, and how that impacts the power of federal agencies and the interpretations of the laws they administer. How this decision may impact current healthcare issues like reimbursement and the U.S. Food and Drug Administration’s (FDA) final rule on regulating laboratory-developed tests as medical devices.The ambiguity of what comes next, and the importance of engaging members of Congress on these important decisions. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Paul Jannetto, Ph.D., director of the Metals Laboratory at Mayo Clinic, and Sarah Erdahl, technical specialist coordinator in the Metals Laboratory. They discuss their unique opportunity to complete testing on locks of hair from the composer Ludwig von Beethoven.
Specific topics of discussion include:
How Mayo Clinic came to be involved in the project, and what historians were hoping to learn from the test results.The technical process of preparing, handling, and testing Beethoven’s hair.What the test results revealed about Beethoven’s health.An overview of Mayo Clinic’s Metals Laboratory and the specialized testing that occurs in the lab. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the summertime activity of COVID-19 and the latest updates with avian influenza (H5N1).
Their discussion includes:
The recent rise in COVID cases and how the new FLiRT variants of the virus are affecting the immune system.Updates on avian influenza activity and the risk for more mutations and human infections.How the U.S. Centers for Disease Control and Prevention (CDC) is responding to the avian flu outbreaks and how laboratories are preparing to support testing needs.Reminders of how to best protect yourself and your loved ones from infectious diseases this summer. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the platform business model and how it’s being used in the healthcare industry to drive innovation and reimagine how care is provided.
Their discussion includes:
Key takeaways from the recent conference hosted by Mayo Clinic Platform.What constitutes a platform and how the model is being implemented in the healthcare industry.How the platform model can transform the way healthcare is delivered, and the implications this transformation has on laboratory medicine and pathology. -
Anastasia Zekeridou, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated panels and methodology boost the accuracy and efficiency of testing for three autoimmune neurology biomarkers. Early diagnosis is key to managing debilitating conditions associated with these antibodies.
(00:32)
Could you please give our listeners an overview of your role at Mayo Clinic?(01:22)
What updates are happening in our laboratory to increase specificity when we receive a patient's serum and CSF for most of the CNS evaluations?(03:48)
Why are these updates and additions important in the larger disease state?
(06:16)
Could you expound upon the relationship between the clinical practice and the lab?(08:32)
What do these changes mean for patient care?(10:27)
What about the inclusion of AMPA in the pediatric evaluation, and the inclusion of IgLON5 with autoimmune axonal?(12:58)
How does your lab discern when it's time to add a biomarker?(15:44)
What are you most excited about? -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss why measles remains a virus of concern, how avian flu continues to spread, and new developments in the federal regulation of laboratory-developed tests.
Their discussion includes:
How a person infected with measles recently traveled through a U.S. airport, and the severity of the measles virus.The continued deadly spread of avian flu among wild birds, domestic poultry, and cattle, and the infection of a third human.Avian flu vaccine development and the importance of emergency preparedness.The American Clinical Laboratory Association’s (ACLA) lawsuit against the U.S. Food and Drug Administration (FDA) regarding the agency’s final rule to treat laboratory-developed tests as medical devices. - Visa fler